BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $32,953,481 | +299.6% | 1,249,658 | +160.6% | 0.16% | +317.9% |
| Q2 2023 | $8,246,557 | -52.3% | 479,451 | -54.0% | 0.04% | -54.7% |
| Q1 2023 | $17,284,418 | +259.6% | 1,042,486 | +65.3% | 0.09% | +218.5% |
| Q4 2022 | $4,806,018 | -41.1% | 630,711 | -23.2% | 0.03% | -38.6% |
| Q3 2022 | $8,161,000 | +892.8% | 821,061 | +806.7% | 0.04% | +1000.0% |
| Q2 2022 | $822,000 | -81.7% | 90,551 | -79.5% | 0.00% | -84.0% |
| Q1 2022 | $4,486,000 | +14.2% | 441,963 | +87.7% | 0.02% | +19.0% |
| Q4 2021 | $3,927,000 | -53.6% | 235,418 | +97.8% | 0.02% | -70.4% |
| Q4 2020 | $8,464,000 | +46.6% | 119,021 | -22.7% | 0.07% | +47.9% |
| Q3 2020 | $5,773,000 | +205.6% | 153,875 | +165.6% | 0.05% | +118.2% |
| Q2 2020 | $1,889,000 | – | 57,941 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |